The IBD growth stock terminal, proven and polished, with a price tag that demands an active process.
MarketSurge scores 72 out of 100 across five pillars, 20 points each.
MarketSurge scores 72, and signal quality leads at 17. It brings Investor's Business Daily's ratings, exclusive reports, automatic pattern recognition and 100+ technical indicators into one charting and screening platform, and its iOS app holds a 4.71 rating from 8,632 ratings. For a CANSLIM trader who uses it daily, the data is hard to match. The score comes from FullStack Alpha desk research plus public user sentiment, and the pillar split is provisional.
Price-to-value is 12 because $149.95 a month, or $1,499 a year, is steep for a screener when Deepvue sells similar screening for $49. Transparency is 13 because the intro offer conflicts on MarketSurge's own page: the banner says 30 days for $24.95, while its FAQ mentions 6 weeks for $49.95. Screenshot the offer you sign up under.
Hover, tap, or focus a card to see who we'd point at this tool — and who should walk away.
The traders who get the most out of MarketSurge.
Where MarketSurge is the wrong spend.
Sentiment pulled from one independent source, kept separate so you can weigh each one yourself.
“Best investing tool! Thank you for providing this app and these services.”Read the original on App Store →
“It's laggy, using different dataset therefore no consistency between app and web version”Read the original on App Store →
Every quote is real and traceable. How we source them →
$24.95 for 30 days
Banner offer at checkout; the site's FAQ also mentions 6 weeks for $49.95, so confirm at signup.
$149.95 / month
Full MarketSurge charts, screens, ratings and reports.
$1,499 / year
Same access billed yearly.
Prices change. Check the vendor’s page before you buy.
One email a week. What we tested, what scored, and what we'd skip. Written for traders, not for clicks.
MarketSurge scores 72, and signal quality leads at 17.
This is an affiliate link. It never affects our score. Why →
